Background: Increasingly, clinicians advocate the use of nonmyeloablative allogeneic stem-cell transplants (NM-allo-SCTs, "mini-transplants") 
Introduction

Allogeneic Stem-Cell Transplantation
Allogeneic stem-cell transplantation (allo-SCT) utilizes hematopoietic stem cells from a nonidentical twin, another sibling or relative, or an unrelated donor to rescue patients from the myelotoxicity caused by high-dose chemotherapy (HDC). 1 Allo-SCT is one method of hematopoietic stem-cell transplantation (HSCT). Another approach to HSCT utilizes autologous stem cells (ie, cells harvested from the patient) for rescue after myeloablative therapy -HDC with autologous stem-cell support. This method produces no graftvs-malignancy effect, and virtually all of the therapeutic efficacy results from the high-dose regimen. In general, HSCT takes advantage of a steep dose-response curve associated with chemotherapy, radiation therapy, or both. Otherwise, without a transplant, such high doses would cause severe myelosuppression. 2, 3 An antitumor immunologic response (graft-vsmalignancy effect) may be associated with allo-SCT. Although there is strong evidence of a graft-vs-leukemia effect in allogeneic transplants for patients with chronic myeloid leukemia (CML), evidence is limited for comparable immunologic responses in patients with multiple myeloma (MM), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), or other hematologic malignancies.
In standard allo-SCT, hematopoietic growth factors are usually given to stimulate engraftment and hematopoietic recovery after infusing the donor cells. Immunosuppressants are administered at the time of stem-cell infusion to reduce the incidence of graft-vshost disease (GVHD), which is a major complication of allo-SCT. Matching donors with recipients according to class I and II HLAs affects the occurrence and severity of acute and chronic GVHD and thus affects the outcome of allo-SCT. Hematopoietic stem cells for allogeneic transplantation may be harvested from bone marrow or peripheral blood. Umbilical cord blood also may be used as a source of stem cells 2 but is not reviewed here.
Nonmyeloablative Conditioning With Allo-SCT
Myeloablative HDC/allo-SCT is associated with a high risk of treatment-related morbidity and mortality (TRM). Even in patients who are otherwise eligible for this procedure, myeloablative HDC/allo-SCT can be toxic. As shown in Table 1 disease (HD). In addition, many patients with malignancies that could potentially be treated with HDC/allo-SCT are not eligible for the procedure due to age (55 years of age is the most common upper limit for eligibility in clinical trials of allo-SCT) or due to coincident disease or poor organ function, which increases the risk for an adverse outcome as a result of treatment-related toxicity. Therefore, treatments are needed that would maintain the high efficacy of myeloablative HDC/allo-SCT with reduced toxicity. For these patients, a nonmyeloablative preparative regimen followed by allogeneic stem-cell transplant (NM-allo-SCT, also known as a "minitransplant" or "transplant lite") has been proposed to decrease the treatment-related morbidity associated with myeloablative chemotherapy while attempting to improve disease-free survival.
In recent years, the need for high-dose conditioning regimens has been challenged. Cures have been observed in patients with advanced malignancies, such as those in whom several courses of aggressive chemotherapy or standard allo-SCT have failed, with adoptive immunotherapy only (ie, using donor-lymphocyte infusion). This observation led to the hypothesis that the efficacy of allo-SCT may derive more from a "graft-vs-leukemia" effect than from the conditioning regimen. If so, long-term disease control might be feasible with less aggressive conditioning regimens. In turn, this might foster the development of safer allo-SCT that can be used for older patients and for those with preexisting organ dysfunction who are currently ineligible for standard HDC/allo-SCT.
Donor allogeneic stem cells can engraft in recipients with the use of less intensive but sufficiently immunosuppressive conditioning regimens to allow graft-host tolerance that yields stable mixed donorhost hematopoietic chimerism. 5 After chimerism develops, donorlymphocyte infusion can be given safely to eradicate malignant cells. Nonmyeloablative preparative regimens have been developed to enable mixed donor-host hematopoietic chimerism while minimizing the toxicity of standard, highdose preparative regimens (Fig 1) . These nonmyeloablative approaches can be divided in three categories 6 : (1) reduced-intensity allo-SCT, (2) pre-allo-SCT host immunosuppression with post-allo-SCT immunosuppression directed at host and donor immune cells, and (3) high-intensity auto-SCT followed by an immunosuppressive cytotoxic allo-BMT alone.
In all of these settings, NM-allo-SCT serves as the basis for subsequent adoptive immunotherapy of the underlying malignancies using donor-lymphocyte infusion. It is important to note that a consistent definition of "nonmyeloablative" regimens is lacking with respect to drug classes, doses, and durations. Multiple regimens have been described, ranging from low-dose total-body irradiation (2 Gy) plus immunosuppressive agents such as mycophenolate mofetil and cyclosporine 7 to regimens using combinations of drugs in doses similar to standard allo-SCT. 8 Thus, these regimens comprise a continuum that overlaps with standard myeloablative regimens.
Methods
Search Methods
We searched the MEDLINE computer database for reports from 1995 through June 2002 using the following search terms: (nonmyeloablat* OR "transplant lite" OR "mini-transplant" OR "mini-allograft*" OR graft-vshost disease (mh)) AND explode hematologic neoplasms (mh) AND human. Similar terms were used to search the EMBASE database. Computer searches were supplemented by manual reviews of bibliographies of selected references, reviews of meeting abstracts from key hematology/oncology meetings, and reviews of Current Contents, an electronic resource that provides access to bibliographic research information.
Study Selection
A flow diagram of our search results and selection process is shown in Fig 2. We initially identified 308 studies for potential retrieval. After further review, we excluded 283 studies, including review articles containing no primary data, abstracts that were later available as full reports, duplicate studies, reports on nonhematologic malignancies, studies on T-cell depletion and donor-lymphocyte infusion, reports on discussions at conferences about NM-allo-SCT, and reports involving fewer than 5 patients. Data were extracted from the remaining 25 studies, which included 23 published as full reports, one abstract, and one letter.
Objectives
Patient Indications
Patient disease was categorized by AML, ALL, HD, NHL, CML, or MM ineligible for HDC/allo-SCT. This category included patients older than 55 years of age and those with concurrent diseases or conditions that increased the risk of treatment-related toxicity. Each hematologic malignancy was considered as a separate indication.
Comparison of Technologies
NM-allo-SCT entails administering reduced-intensity preparative regimens for allo-SCT that provide sufficient immunosuppression against host cells before transplants and against host and donor cells after transplants, with the net effect of establishing mutual grafthost tolerance to yield stable mixed donor-host hematopoietic chimerism. The goal of establishing chimerism is to allow the safe administration of donorlymphocyte infusion to eradicate malignant cells. To date, NM-allo-SCT has been used predominantly in hematologic malignancies. Since so few studies reported using this technology in solid tumors, our systematic review focused on the safety and efficacy of NM-allo-SCT in hematologic malignancies.
Alternatives to NM-allo-SCT for patients with AML, ALL, HD, NHL, or MM ineligible for HDC/allo-SCT include HDC followed by autologous stem-cell transplantation (HDC/auto-SCT) and conventional-dose treatment. For patients with CML who are ineligible for HDC/allo-SCT, conventional-dose therapy (with imatinib mesylate [Gleevec] ) is an alternative to NM-allo-SCT.
Health Outcomes
The goal of NM-allo-SCT is to improve the duration of survival either by directly altering the course of disease or by increasing the time to relapse or progression and thus forestalling the natural progression. Intermediate outcomes related to the effects of treatment on disease -complete remission, partial remission, and relapse rate -were also considered. Since NM-allo-SCT attempts to induce tolerance between the recipient and donor, data on mixed chimerism are also of interest. Adverse health outcomes of NM-allo-SCT are treatment-related morbidity and mortality, including the incidence or prevalence of acute and chronic GVHD, veno-occlusive disease, and grade III/IV toxicity according to the National Cancer Institute toxicity criteria.
Specific Questions
Does NM-allo-SCT improve the net health outcome of patients with AML, ALL, HD, NHL, CML, or MM who are ineligible for HDC/allo-SCT? Net health outcome includes an analysis of disease-free survival or overall survival balanced against treatment-associated toxicity, acute and chronic complications, and death. Results were compared with the natural history of each disease or the expected outcome of conventional treatment in patients with advanced hematologic malignancies.
Potentially appropriate studies to be included in the systematic review (n=25) Potentially revelent studies identified and screened for retrieval (n=308) Compared to treatment with the established alternatives, does NM-allo-SCT improve the net health outcome of patients with AML,ALL, HD, NHL, CML, or MM who otherwise are eligible for HDC/allo-SCT? Again, net health outcome includes an analysis of disease-free survival or overall survival balanced against treatmentrelated toxicity, complications, and death.
Results
Overview
Data were obtained from the 25 publications described. No prospective, randomized, controlled trials addressed the specific questions of this review. Only two studies 9,10 reported retrospective comparisons with historical controls given standard allo-SCT, without matching in each comparison. All other studies reported case series, occasionally discussing their results in reference to outcomes of standard allo-SCT. Therefore, conclusions are limited from the overall body of evidence in this area.
Only four papers 10-13 and one abstract 14 reported results of NM-allo-SCT in a single malignancy. All other studies pooled the results from several diseases, which presented difficulties in data extraction. Additionally, many studies pooled results across varied conditioning regimens, which prevented comparison of outcomes as a function of the regimen. The sample size was small in most studies; only four included more than 10 patients with the same hematologic malignancy.
11,13-15
The largest report included 86 patients and various hematologic malignancies. 15 The largest study on a single malignancy included 31 patients with MM.
10 Table 2 summarizes the number of patients who received NM-allo-SCT in specific hematologic malignancies. The studies were heterogeneous, largely because they combined patients with several diseases in the same analysis and differed in patient selection criteria, conditioning regimens, and timing of NM-allo-SCT (after autologous transplant, in first or second remission, or after relapse).
Appendix 1A-C summarize the evidence from each of the 25 studies. The median age was approximately 51 years (range 1-72 years). The majority of patients were over 40 years of age. Multiple studies reported on patients older than age 50, who are rarely given standard allo-SCT. The International Bone Marrow Transplant Registry reports a category for patients over age 50 but does not provide details on the potential number of patients who might be older than age 50. Estimating the number of patients older than 50 years of age at the time of transplantation, as well as their outcomes, was difficult.
Of the 603 patients who received NM-allo-SCT, 158 were women, 266 were men, and 179 were not classified by gender. In four studies, patients with comorbid conditions were eligible for treatment; such patients routinely are excluded from standard allo-SCT. However, data on the specific comorbid conditions were scant. The number of patients who had undergone transplantation with special comorbid conditions was unclear. Appendix 2 provides data on eligibility criteria as reported in the studies included in this systematic review.
Various conditioning regimens were utilized (Appendix 3), but most studies used cyclophosphamide/ fludarabine. In most studies, donors were HLA-compatible, but several studies used matched unrelated donors (MUDs) and/or donors with one or two mismatched antigens. In total, 118 patients underwent transplants from MUDs. It was not possible to extract data on TRM and other outcomes by HLA status.
Few studies reported data on overall survival and disease-free survival beyond 1 year. tion in patients receiving reduced conditioning regimens compared to those receiving conventional BMT was 78% and 58% at 1 year and 77% and 74% at 2 years, respectively. Pawson et al 18 reported the longest followup survival data for 14 patients who underwent NMallo-SCT after previous conventional SCT failed. At 58 months, the actuarial survival rate was 60%, the diseasefree survival rate was 26%, and no treatment-related deaths had occurred. Corradini and coworkers 19 reported an overall survival rate of 53% in 45 patients at 24 months. Michallet et al 20 reported an overall survival rate of 31% at 2 years using NM-allo-SCT in several hematologic malignancies. Finally, Nagler and colleagues 21 utilized MUD NM-allo-SCT in 16 patients and reported overall and disease-free survival rates of 75% and 60%, respectively, at 36 months.
Only six studies reported data on median survival or the range of survival. [10] [11] [12] 14, 17, 22 In these studies, survival ranged from approximately 2 months to longer than 24 months. No long-term survival outcomes are available at this time.
Complete remission rates were reported in 21 studies, which varied from 0% (0 of 2 patients with myelodysplastic syndrome (MDS) who underwent NMallo-SCT) to 100% in a single case report. Most studies reported complete remissions in 40% to 70% of patients, but sample sizes were too small to permit meaningful conclusions. It is noted that chimerism, another intermediate outcome, was achieved in nearly all patients. Data on relapse were inadequately reported. Although most reports focused on successful cases, relapse was reported in 6 (33%) of 18 patients in one of the few large series on patients with a single malignancy (CML).
11
Most studies reported data on TRM, which varied from none in a single case report to 3 (43%) of 7 patients. 16 Causes of TRM included infection, GVHD, and organ failure. However, patient enrollment in each of these studies was insufficient to permit conclusions regarding TRM of NM-allo-SCT.
Graft-vs-host disease is a major complication of allo-SCT. Data are insufficient to permit conclusions, but it is hypothesized that inducing chimerism may reduce the incidence of GVHD. However, available data do not suggest that the incidence of acute GVHD (grade II-IV) was reduced; the incidence of acute GVHD varied from 0% in a single case report to 100% (5 of 5 patients) in a small series. The incidence of extensive chronic GVHD varied from 0% in a single case report to 66% (12 of 18 patients) in the largest series in a single disease.
11 Because most studies did not report the incidence of veno-occlusive disease, we could not determine if it did not occur or if it did occur but was not reported. Data on morbidity using grades III and IV toxicity according to the National Cancer Institute toxicity criteria suggest that NM-allo-SCT is more tolerable than standard allo-SCT. Most reports indicated that grades III and IV toxicity occurred in less than 15% of cases, although several single case studies reported toxic effects of NM-allo-SCT. Table 3 presents an overview of aggregate data that were extractable from published reports. Due to considerable heterogeneity among studies, caution should be exercised when interpreting the summary of evidence presented in this table. Nevertheless, it is notable that TRM remains high (32%; 95% CI, 28% to 37%) in this heavily pretreated and generally older population with many comorbidities. Also, it is noted that this aggregated TRM pool included HLA-matched sibling donors as well as MUDs. Overall, there were 118 NM-allo-SCT with MUDs. We could not reliably compare TRM after transplants from MUDs with TRM after transplants from HLA-identical siblings.
Standard allo-SCT is likely associated with a greater risk of TRM (ranging from 10% to 56%) when compared with NM-allo-SCT (Table 1) , even though this procedure is usually used in younger patients with no comorbid conditions. The incidence of acute GVHD following NM-allo-SCT was similar to that seen in standard allo-SCT, while the incidence of chronic GVHD was lower Again, direct data are lacking for definitive conclusions. Table 3 also summarizes data on relapse, which occurred in approximately 15% of treated patients (95% CI, 11% to 19%). Data on long-term benefits are even more limited. Survival beyond 1 year was reported in few studies.
10-12,17 Thus, it was not possible to combine data on disease-free survival and median survival at the time of this review. Across multiple reports, complete remission was reported in 215 (45%) of 482 patients with a variety of malignancies.
The current body of evidence regarding NM-allo-SCT is insufficient to permit definitive conclusions regarding potential advantages of this treatment compared with standard allo-SCT. Nevertheless, this treatment approach was largely studied in a population of patients generally deemed ineligible for standard allo-SCT. Unfortunately, most reports omitted the criteria to define "ineligibility" for standard allo-SCT. Clinical judgment, patient preference, or both likely influenced patient selection. For example, prior autologous stemcell support has been a relative contraindication to standard allo-SCT in some studies.
Available data suggest that toxicity with NM-allo-SCT might be lower than that observed with standard allo-SCT. Reports that some studies used NM-allo-SCT as an outpatient treatment support this possibility. For example, in a study by McSweeney et al, 5 53% of patients were treated entirely as outpatients with minimal toxicity and no alopecia, painful mucositis, severe nausea and vomiting, or toxicities to other vital organs. They also reported that only 23% of patients undergoing NM-allo-SCT received platelet transfusions compared with 100% of patients undergoing conventional allo-SCT. 36 Similarly, only 63% of patients treated with NM-allo-SCT received red blood cell transfusions compared with 96% of patients given conventional grafts. However, this study used the lowest-intensity conditioning regimen of all others reported; pancytopenia was minimal. Using a more intensive regimen (fludarabine, busulfan, and cyclophosphamide), Ruiz-Arguelles and colleagues 37 reported that outpatient transplants were feasible in 21 of 25 patients. Several reports noted that toxicity was minimal or acceptable, but in many cases details were not provided. Pancytopenia frequently occurred, indicating considerable myelosuppression after most NM-allo-SCT regimens. Currently, it is also unclear whether this potentially reduced toxicity will yield an overall net benefit in health outcome since data on benefits and harms are insufficient.
Evidence by Disease Table 4 summarizes available data from the 25 selected publications according to malignancy. Note that this table aggregates and pools data from multiple references of considerable heterogeneity concerning Table 4 . -NM-allo-SCT: Overview of Published Evidence in Hematologic Malignancies According to Specific Diseases* differences in patient selection criteria, conditioning regimens, timing of NM-allo-SCT (after auto-SCT, in first or second remission, or after relapse), and comorbid conditions (age and exclusion criteria due to other organ dysfunction). Therefore, these data should be interpreted with caution.
No published reports have compared the effects of NM-allo-SCT with those of standard allo-SCT, either respectively or prospectively, in patients eligible for standard allo-SCT. Likewise, data are lacking to compare outcomes of NM-allo-SCT with those of standard treatment. Thus, definitive conclusions are not possible regarding net health outcomes in patients ineligible for standard allo-SCT. Overall, the available evidence on effects of NM-allo-SCT in specific hematologic malignancies is limited and of poor quality.
Conclusions
Firm recommendations regarding the net benefits of NM-allo-SCT in the management of hematologic malignancies are precluded by the lack of comparative data, the extreme heterogeneity of the studies, the short follow-up, and the relatively small number of patients studied to date. Initiation of disease-specific studies with clearly defined eligibility criteria are needed to further elucidate the safety and efficacy of NM-allo-SCT. 
